Best Healthcare Companies in Nanjing, China
The 41 best Healthcare companies in Nanjing, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Jiangsu Vcare Pharmatech.
Ranked: Best Healthcare companies in Nanjing
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Jiangsu Vcare Pharmatech CDMO manufacturing APIs | $107M | 31 mo ago | Series C | — | 2010 | — | 66 patents Small‑molecule inhibitors for immune and oncology targets (JAK, BTK, TRK, ER, MAT2A). | — |
| 2 | Eaglenos Manufacturer of diagnostic test kits | $21M | 39 mo ago | Series A | — | 2017 | WordPress Block EditorWordPressMySQL+13 | — | 2 launchs |
| 3 | Lansion Biotechnology Provider of microfluidics-based in vitro diagnostic reagents and instruments | $14M | 47 mo ago | Series D | Jeffery Chen Co-founder | 2016 | — | 101 patents Patents concentrated in transport & manufacturing processes | — |
| 4 | Nanjing F&S Pharmatech Manufacturer of APIs and pharmaceutical intermediates | $7M | 77 mo ago | Series B | Yuan Fang Founder & Chairman | 2015 | — | — | — |
| 5 | Puguang Biotechnology Developer and manufacturer of in-vitro diagnostic instruments and reagents for medical and veterinary use | $6M | 60 mo ago | Seed | — | 2017 | — | — | — |
| 6 | TriApex Provider of contract based research, regulatory strategy, clinical trials, and laboratory services | — | 40 mo ago | Series C | Zhang Xuefeng CEO | 2008 | — | — | — |
| 7 | Nanjing Synthgene Medical Technology R&D company focused on manufacturing of diagnostic products for multiple therapeutic areas | — | 52 mo ago | Series A | Tong Kun Founder | 2018 | BootstrapNginxOpenResty+11 | — | — |
| 8 | Jiangsu Synthgene Biotechnology CRO focused on development of invitro diagnostic reagents | — | 52 mo ago | Series A | — | 2018 | — | — | — |
Top 12 Healthcare companies in Nanjing
#1
Series C · Nanjing, Jiangsu · founded 2010 · 500 employees$107.3Mraised▾
CDMO manufacturing APIs
- Jan 2024Series C$63.3M
- Dec 2022Series B$28.6M
- Jul 2021Series B$15.5M
#2
Series A · Nanjing, Jiangsu · founded 2017 · 220 employees$21.2Mraised▾
Manufacturer of diagnostic test kits
- May 2023Series A$21.2M
#3
Series D · Nanjing, Jiangsu · founded 2016$14.2Mraised▾
Lansion Biotechnology provides microfluidics-based in vitro diagnostic reagents and instruments. The company offers devices like incubators, molecular diagnostic analyzers, fluorescence immunoassay analyzers, immunochromatographers, etc. The company has ISO13485 certificate.
- Sep 2022Series D—
- 2022Series D—
- Dec 2020Series D—
- Nov 2019Series C$14.2M
#4
Seed · Nanjing, Jiangsu · founded 2017 · 100 employees$6.2Mraised▾
Developer and manufacturer of in-vitro diagnostic instruments and reagents for medical and veterinary use. It provides diagnostic solutions, including instruments and reagents, for medical and veterinary applications. The company develops and produces diagnostic tests for inflammation, metabolism, anemia, hormones, hypertension, thyroid function, cytokines, prenatal screening, cardiovascular conditions, and infectious diseases. It also offers dry chemistry luminescence ODM services and freeze-dried microsphere CDMO services, along with related products for drug testing, food testing, livestock monitoring, environmental monitoring, and medical aesthetics.
- Aug 2021Seed$6.2M
#5
Series B · Nanjing, Jiangsu · founded 2015$7.3Mraised▾
Developer of differentiated generic drugs and pharmaceutical intermediates in China. The company focuses on the research and development of advanced pharmaceutical chemical and intermediates including sacubitril, diphenyl piperidine methanol and other methanol-based intermediates, providing reliable products for R&D centers and generic drug developers to shorten development cycle and reduce product cost.
- Mar 2020Series B—
- Sep 2018Series A$7.3M
#6
Series C · Nanjing, Jiangsu · founded 2008—raised▾
Provider of contract based research, regulatory strategy, clinical trials, and laboratory services
- Apr 2023Series C—
- Nov 2021Seed—
#7
Series A · Nanjing, Jiangsu · founded 2018—raised▾
R&D company focused on manufacturing of diagnostic products for multiple therapeutic areas
#8
Series A · Nanjing, Jiangsu · founded 2018 · 22 employees—raised▾
CRO focused on development of invitro diagnostic reagents
- Apr 2022Series A—
- Series A—
#9
Series B · Nanjing, Jiangsu · founded 2015—raised▾
Manufacturer of diagnostic products
- Jul 2021Series B—
#10
Public · Nanjing, Jiangsu · founded 2013 · 511 employees—raised▾
Manufacturer of pelvic floor diagnosis and treatment devices
- Sep 2020Seed—
#11
Seed · Nanjing, Jiangsu · founded 2015 · 40 employees—raised▾
Developer of drugs intended to treat cancer. The company focuses on the use of detection technology to accurately target the infected cell, enabling physicians to treat their patients in an enhanced way.
- Jan 2019Seed—
#12
Series A · Nanjing, Jiangsu · founded 2014 · 28 employees—raised▾
Forssmann Medical has developed interventional devices (projection infrared angiography system, wireless pressure pump, a guide wire for intracranial vessels), diagnostic devices (wireless blood flow reserve fraction micro-guidewire, intravascular optical tomography), and treatment series (single use saphenous vein extraction device, vertebral artery stent, inferior vena cava filter, intracranial mesh stent).
- Oct 2018Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Healthcare coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.